Comparison of glucose concentrations in canine whole blood, plasma, and serum measured with a veterinary point-of-care glucometer

2021 ◽  
pp. 104063872110197
Author(s):  
Natalie D. Suchowersky ◽  
Elizabeth A. Carlson ◽  
Hollie P. Lee ◽  
Ellen N. Behrend
Keyword(s):  
Blood Plasma ◽  
Glucose Concentration ◽  
Whole Blood ◽  
Point Of Care ◽  
Serum Glucose ◽  
Glucose Measurement ◽  
Strongly Correlated ◽  
Concordance Correlation ◽  
Biochemical Analyzer ◽  
Mean Differences

Previous studies have determined that, compared to whole blood, serum or plasma used in a portable blood glucometer (PBG) may provide more accurate results. We investigated the accuracy of a veterinary PBG (AlphaTRAK 2; Zoetis) for the measurement of glucose concentrations in serum, plasma, and whole blood compared to plasma glucose concentration measured by a biochemical analyzer. Blood samples from 53 client-owned dogs were collected. Lin concordance correlation coefficient (ρc) and Bland–Altman plots were used to determine correlation and agreement between the results obtained for the different sample types. Glucose concentration in whole blood measured by the veterinary PBG was more strongly correlated with the glucose concentration measured by the biochemical analyzer (ρc = 0.92) compared to plasma and serum glucose concentrations (ρc = 0.59 and 0.57, respectively). The mean differences between the glucose concentrations in whole blood, plasma, and serum measured by the veterinary PBG and the glucose concentration determined by the biochemical analyzer were 1.0, 6.3, and 6.7 mmol/L (18, 113, and 121 mg/dL), respectively. Our findings suggest that, when using this veterinary PBG, the accuracy of a glucose measurement obtained is higher when using whole blood compared to plasma or serum. Use of whole blood allows for more correct assessment and diagnosis, which are necessary for appropriate therapeutic intervention.

scholarly journals EVALUASI ANALITIK POCT METODE GLUCOSE DEHYDROGENASE PARAMETER GLUKOSA PADA SPESEIMEN SERUM DAN PLASMA EDTA

2021 ◽  
Vol 9 (1) ◽  
pp. 26-36
Author(s):  
Suryanata Kesuma ◽  
Didi Irwadi ◽  
Nia Ardelia
Keyword(s):  
Health Care ◽  
Whole Blood ◽  
Communicable Disease ◽  
Point Of Care ◽  
Glucose Dehydrogenase ◽  
Serum Glucose ◽  
Glucose Measurement ◽  
Glucose Testing ◽  
Analytic Evaluation ◽  
Health Care Institutions

Diabetes is a non-communicable disease that can be prevented and detected as early as possible by routine glucose checks. Point Of Care Testing (POCT) as a diabetes test screening tool is widely used by health care institutions and is even used independently by the wider community. Blood glucose can be measured by serum, plasma, and whole blood specimens. The standard specimen for glucose measurement using POCT is whole blood. Based on the author's survey, the use of the POCT tool in several health care institutions was not following the insert of the tool kit, one of which was the type of specimen used. Many laboratories use EDTA serum and plasma specimens for glucose testing using the POCT device. There are many methods used in the POCT tool, one of these methods is the glucose dehydrogenase method. Therefore analytic evaluation is necessary to ensure the accuracy and accuracy of laboratory examination results in glucose examination. This type of research is the analytical method with a comparative design. The data was collected using the total sampling method. The data is reported using Microsoft Excel and SPSS applications. The number of samples for analytic evaluation was 40 samples. Based on the results of tests performed in duplicate, there were clinical differences in glucose values using serum and plasma EDTA samples so that the use of these samples was not suitable for use for diagnostic purposes using the POCT glucose dehydrogenase method. There was a statistical difference in serum glucose and plasma EDTA against whole blood that was examined using the POCT glucose dehydrogenase method with a correlation value (R) of 0.9722 and 0.9695.

scholarly journals Detection of codeine and fentanyl in saliva, blood plasma and whole blood in 5-minutes using a SERS flow-separation strip

The Analyst ◽  
2019 ◽  
Vol 144 (18) ◽  
pp. 5449-5454 ◽  
Author(s):  
Chetan Shende ◽  
Carl Brouillette ◽  
Stuart Farquharson
Keyword(s):  
Blood Plasma ◽  
Flow Separation ◽  
Whole Blood ◽  
Point Of Care ◽  
Simple Point

A rudimentary flow strip, based on SERS, was developed and used to measure drugs, such as fentanyl, in saliva, plasma, and blood. Fully developed, the strip could be used with hand-held Raman spectrometers as a simple, point-of-care drug analyzer.

scholarly journals Clinical performance of two EUA-approved anti-COVID-19 IgG/IgM rapid lateral flow immunoassays using whole blood finger-sticks

2021 ◽  
Author(s):  
Christian Tagwerker ◽  
Irfan Baig ◽  
Eric Brunson ◽  
Kristine Mundo ◽  
Dava Dutra-Smith ◽  
...  
Keyword(s):  
Blood Plasma ◽  
Whole Blood ◽  
Clinical Performance ◽  
Point Of Care ◽  
Cost Effective ◽  
Lateral Flow ◽  
Simultaneous Application ◽  
Igm Elisa ◽  
Elisa Testing ◽  
Finger Stick

Serological, or antibody, tests detect immunoglobulins produced by the hosts plasma B cells following exposure to foreign antigens. Venipuncture blood draws to collect human venous whole blood, plasma from anticoagulated blood (Li+ heparin, K2EDTA and sodium citrate), or serum are commonly utilized and require refrigerated temperatures during transport to the testing facility. Subsequent laboratory testing by enzyme-linked immunosorbent assays (ELISA) or chemiluminescence immunoassays (CLIA) can take an additional 2-5 hours. In the context of the COVID-19 pandemic, rapid diagnostic tests (RDT) to be used in point-of-care (POC) and remote settings have become essential during mandatory quarantine and isolation periods. RDTs allowed for more cost-effective testing using less collection materials with an immediate (5-10 minutes) test result. However, the majority of emerging RDTs receiving Emergency Use Authorization (EUA) approval by the Food and Drug Administration (FDA) for qualitative detection and differentiation of IgM and IgG antibodies to SARS-CoV-2 were only approved for use in human venous whole blood, plasma or serum. In this study we summarize performance characteristics of one RDT (COVID-19 IgG/IgM lateral flow immunoassay rapid cassette) to another by simultaneous application of whole blood finger-stick specimens (n = 32). The study was performed over 5 different days, with daily quality controls consisting of serum previously verified to be positive or negative by COVID-19 IgG/IgM ELISA testing.

An innovative blood plasma separation method for a paper-based analytical device using chitosan functionalization

The Analyst ◽  
2020 ◽  
Vol 145 (16) ◽  
pp. 5491-5499
Author(s):  
Dami Kim ◽  
SeJin Kim ◽  
Sanghyo Kim
Keyword(s):  
Blood Plasma ◽  
Glucose Concentration ◽  
Whole Blood ◽  
Separation Method ◽  
Plasma Separation ◽  
Blood Plasma Separation ◽  
Analytical Device

This study describes a microfluidic paper-based analytical device (μPAD) for separating plasma from whole blood and measuring glucose concentration.

scholarly journals Initial clinical experience with the Quantra QStat System in adult trauma patients

2020 ◽  
Vol 5 (1) ◽  
pp. e000581
Author(s):  
Edward A Michelson ◽  
Michael W Cripps ◽  
Bradford Ray ◽  
Deborah A Winegar ◽  
Francesco Viola
Keyword(s):  
Clinical Experience ◽  
Whole Blood ◽  
Point Of Care ◽  
Clinical Settings ◽  
Trauma Patients ◽  
Strongly Correlated ◽  
Level Of Evidence ◽  
Multicenter Observational Study ◽  
Level Ii ◽  
Critical Bleeding

BackgroundWhole blood viscoelastic testing (VET) devices are routinely used in a variety of clinical settings to assess hemostasis. The Quantra QStat System is a cartridge-based point of care VET device that measures changes in clot stiffness during coagulation and fibrinolysis using ultrasound detection of resonance. The objective of this study was to assess the ability of the Quantra QStat System to detect coagulopathies in trauma patients.MethodsA multicenter observational study was conducted on adult subjects at two level 1 trauma centers. For each subject, whole blood samples were drawn upon arrival to the emergency department and again, in some cases, after administration of blood products and/or antifibrinolytics. Samples were analyzed on the Quantra in parallel to ROTEM delta. The QStat cartridge provides measures of Clot Time (CT), Clot Stiffness (CS), Fibrinogen and Platelet Contributions to clot stiffness (FCS and PCS), and Clot Stability to Lysis (CSL). Data analyses included linear regression of Quantra and ROTEM parameters and an assessment of the concordance of the two devices for the assessment of hyperfibrinolysis.ResultsA total of 56 patients were analyzed. 42% of samples had a low QStat CS value suggestive of an hypocoagulable state. The low stiffness values could be attributed to either low PCS, FCS or combination. Additionally, 13% of samples showed evidence of hyperfibrinolysis based on the QStat CSL parameter. Samples analyzed with ROTEM assays showed a lower prevalence of low CS and hyperfibrinolysis based on EXTEM and FIBTEM results. The correlation of CS, FCS and CT versus equivalent ROTEM parameters was strong with r-values of 0.83, 0.79 and 0.79, respectively.DiscussionThis first clinical experience with the Quantra in trauma patients showed that the QStat Cartridge was strongly correlated with ROTEM parameters and that it could detect coagulopathies associated with critical bleeding.Level of evidenceDiagnostic test, Level II.

Sign in / Sign up

Export Citation Format

Share Document